Hospital Mortality in Patients Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK)
This study has the following objective:
To identify related factors to hospital mortality in patients with ST-segment elevation acute myocardial infarction submitted to pharmacoinvasive strategy within a structured healthcare network.
Acute Coronary Syndrome
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration:||15 Days|
|Official Title:||Hospital Mortality After ST Segment Elevation Acute Myocardial Infarction Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK): Analysis of 398 Patients.|
- Hospital Mortality [ Time Frame: During hospital stay,an expected average of 15 days ]
|Study Start Date:||November 2010|
|Study Completion Date:||October 2012|
|Primary Completion Date:||October 2012 (Final data collection date for primary outcome measure)|
Primary percutaneous coronary intervention is the main therapy for patients with ST-segment elevation acute myocardial infarction. However, a significant portion of these patients won't receive optimal treatment due to the small number of tertiary centers with interventional laboratories available for 24 hours a day, 7 days a week.
Specially in large urban centers and rural areas, where tertiary care hospitals are restricted to a specific region, alternative approaches must be developed. The pharmacoinvasive strategy has emerged as an alternative for patients admitted to primary care centers. It is based in up-front intravenous thrombolytic therapy and transfer to a tertiary center where early, systematic, coronary intervention will be performed between 3 to 24 hours after the administration of thrombolytic drugs, even in cases in which successful reperfusion was obtained.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01791764
|Federal University of Sao Paulo|
|Sao Paulo, SP, Brazil|
|Principal Investigator:||Felipe JA Falcao||Federal University of Sao Paulo|
|Principal Investigator:||Claudia MR Alves, Doctor||Federal University of Sao Paulo|
|Study Director:||Antonio CC Carvalho||Federal University of Sao Paulo|
|Study Director:||Adriano HP Barbosa||Federal University of Sao Paulo|